ECSP077997A - Moduladores de alquilquinolina y alquilquinazolina cinasa - Google Patents

Moduladores de alquilquinolina y alquilquinazolina cinasa

Info

Publication number
ECSP077997A
ECSP077997A EC2007007997A ECSP077997A ECSP077997A EC SP077997 A ECSP077997 A EC SP077997A EC 2007007997 A EC2007007997 A EC 2007007997A EC SP077997 A ECSP077997 A EC SP077997A EC SP077997 A ECSP077997 A EC SP077997A
Authority
EC
Ecuador
Prior art keywords
compounds
trkb
flt3
kit
modulators
Prior art date
Application number
EC2007007997A
Other languages
English (en)
Inventor
Michael David Gaul
Guozhang Xu
Christian Andrew Baumann
Kevin Douglas Kreutter
Nand Baindur
Alexander J Kim
Robert W Tuman
Dana L Johnson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP077997A publication Critical patent/ECSP077997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos alquinolina y alquinazolina de fórmula I:en donde R1, R2, R3, B, Z, G, Q y X son como se define en la presente, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de FLT3 y/o c?kit y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad cinasa de FLT3 y/o c kit y/o TrkB en una célula o un sujeto, y el uso de dichos compuestos para la prevención o tratamiento en un sujeto de un trastorno proliferante celular y/o trastornos relacionados a FLT3 y/o c kit y/o TrkB; la presente invención se refiere además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para el tratamiento de condiciones tales como cánceres y otros trastornos proliferantes celulares.
EC2007007997A 2005-06-10 2007-12-10 Moduladores de alquilquinolina y alquilquinazolina cinasa ECSP077997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
ECSP077997A true ECSP077997A (es) 2008-01-23

Family

ID=37038081

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007997A ECSP077997A (es) 2005-06-10 2007-12-10 Moduladores de alquilquinolina y alquilquinazolina cinasa

Country Status (18)

Country Link
US (1) US8071768B2 (es)
EP (1) EP1893598A1 (es)
JP (1) JP2009501135A (es)
KR (1) KR20080028912A (es)
AR (1) AR054386A1 (es)
AU (1) AU2006257945A1 (es)
BR (1) BRPI0611964A2 (es)
CA (1) CA2611242A1 (es)
CR (1) CR9652A (es)
EA (1) EA200800017A1 (es)
EC (1) ECSP077997A (es)
GT (1) GT200600251A (es)
IL (1) IL187692A0 (es)
NO (1) NO20080174L (es)
PE (1) PE20070014A1 (es)
TW (1) TW200716599A (es)
UY (1) UY29588A1 (es)
WO (1) WO2006135721A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8760507B2 (en) * 2008-08-05 2014-06-24 Inspectron, Inc. Light pipe for imaging head of video inspection device
EP2518064A1 (en) * 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
BR112013006953A2 (pt) 2010-09-29 2016-07-26 Intervet Int Bv composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112014001977A2 (pt) 2011-07-27 2017-02-21 Ab Science inibidores seletivos de proteína quinase
HRP20181448T1 (hr) * 2012-11-20 2018-11-02 Merial, Inc. Antihelmintski spojevi i sastavi te postupak za njihovu uporabu
EP3059227B1 (en) * 2013-10-16 2019-06-26 FUJIFILM Corporation Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor
WO2015092610A1 (en) * 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3858813A4 (en) * 2018-09-27 2022-06-22 Shenzhen Chipscreen Biosciences Co., Ltd. QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
US20220154220A1 (en) * 2018-12-21 2022-05-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Small molecules for increasing precise genome editing efficiency

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
ATE230740T1 (de) 1996-04-12 2003-01-15 Sumitomo Pharma Piperidinylpyrimidine derivate
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
DK0882717T3 (da) 1996-10-01 2010-12-13 Kyowa Hakko Kirin Co Ltd Nitrogenholdige heterocykliske forbindelser
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
WO2002016360A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
DK1309569T3 (da) 2000-08-18 2011-01-24 Millennium Pharm Inc N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamidderivater som PDGFRs-inhibitorer
AU2002226877B2 (en) 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AU2002220276A1 (en) 2000-12-12 2002-06-24 Neurogen Corporation Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
HUP0500111A3 (en) 2001-12-27 2009-10-28 Theravance Indolinone derivatives useful as protein kinase inhibitors
MXPA04007459A (es) 2002-02-01 2005-09-08 Astrazeneca Ab Compuestos de quinazolina.
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MXPA05000081A (es) 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7470709B2 (en) 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis

Also Published As

Publication number Publication date
TW200716599A (en) 2007-05-01
PE20070014A1 (es) 2007-03-08
KR20080028912A (ko) 2008-04-02
US8071768B2 (en) 2011-12-06
CA2611242A1 (en) 2006-12-21
US20060281772A1 (en) 2006-12-14
UY29588A1 (es) 2006-10-02
NO20080174L (no) 2008-02-19
AR054386A1 (es) 2007-06-20
EP1893598A1 (en) 2008-03-05
WO2006135721A1 (en) 2006-12-21
JP2009501135A (ja) 2009-01-15
IL187692A0 (en) 2008-08-07
CR9652A (es) 2008-09-09
AU2006257945A1 (en) 2006-12-21
EA200800017A1 (ru) 2008-08-29
GT200600251A (es) 2007-01-12
BRPI0611964A2 (pt) 2009-01-27

Similar Documents

Publication Publication Date Title
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
ECSP077992A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP109953A (es) Derivados de piridazinona
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP10010361A (es) Derivados de piridazinona
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos
NI200700312A (es) Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa